BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are used in a variety of malignancies.
Infections have been reported with these drugs. We performed an up-to-date meta-analysis to further characterise the risk of infections in cancer patients treated with these agents.
METHODS: Pubmed and oncology conferences' proceedings were searched for studies from January 1966 to June 2012. Studies were limited to phase II and III randomised controlled trials (RCTs) of everolimus or temsirolimus reporting on cancer patients with adequate safety profiles. Summary incidences, relative risks (RRs), and 95% confidence intervals (CIs) were calculated.
RESULTS: A total of 3180 patients were included. The incidence of all-grade and high-grade infections due to mTOR inhibitors was 33.1% (95% CI, 24.5-43.0%) and 5.6% (95% CI, 3.8-8.3%), respectively. Compared with controls, the RR of all-grade and high-grade infections due to mTOR inhibitors was 2.00 (95% CI, 1.76-2.28, P< 0.001) and 2.60 (95% CI, 1.54-4.41, P< 0.001), respectively. Subgroup analysis found no difference in incidences or risks between everolimus and temsirolimus or between different tumour types (renal cell carcinoma (RCC) vs non-RCC). Infections included respiratory tract (61.7%), genitourinary (29.4%), skin/soft tissue (4.2%), and others (4.9%).
CONCLUSION: Treatment with mTOR inhibitors is associated with a significant increase in risk of infections. Close monitoring for any signs of infections is warranted.
Written by:
Kaymakcalan MD, Je Y, Sonpavde G, Galsky M, Nguyen PL, Heng DY, Richards CJ, Choueiri TK. Are you the author?
Department of Pharmacy, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Reference: Br J Cancer. 2013 Jun 25;108(12):2478-84.
doi: 10.1038/bjc.2013.278
PubMed Abstract
PMID: 23736025
UroToday.com Renal Cancer Section
